372 related articles for article (PubMed ID: 25927031)
21. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.
Surcel CI; van Oort IM; Sooriakumaran P; Briganti A; De Visschere PJ; Fütterer JJ; Ghadjar P; Isbarn H; Ost P; van den Bergh RC; Yossepowitch O; Giannarini G; Ploussard G;
Urol Oncol; 2015 Jun; 33(6):265.e1-7. PubMed ID: 25238700
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.
Jiborn T; Bjartell A; Abrahamsson PA
Urology; 1998 Apr; 51(4):585-9. PubMed ID: 9586611
[TBL] [Abstract][Full Text] [Related]
23. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling.
Lin TP; Chang YT; Lee SY; Campbell M; Wang TC; Shen SH; Chung HJ; Chang YH; Chiu AW; Pan CC; Lin CH; Chu CY; Kung HJ; Cheng CY; Chang PC
Oncotarget; 2016 May; 7(18):26137-51. PubMed ID: 27034167
[TBL] [Abstract][Full Text] [Related]
24. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
Humez S; Monet M; Legrand G; Lepage G; Delcourt P; Prevarskaya N
Endocr Relat Cancer; 2006 Mar; 13(1):181-95. PubMed ID: 16601287
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
[TBL] [Abstract][Full Text] [Related]
27. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
28. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells.
Nam RK; Benatar T; Amemiya Y; Wallis CJD; Romero JM; Tsagaris M; Sherman C; Sugar L; Seth A
Oncotarget; 2018 Apr; 9(27):19159-19176. PubMed ID: 29721191
[TBL] [Abstract][Full Text] [Related]
30. Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells.
Courel M; El Yamani FZ; Alexandre D; El Fatemi H; Delestre C; Montero-Hadjadje M; Tazi F; Amarti A; Magoul R; Chartrel N; Anouar Y
Eur J Cancer; 2014 Nov; 50(17):3039-49. PubMed ID: 25307750
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.
Patel GK; Chugh N; Tripathi M
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547070
[TBL] [Abstract][Full Text] [Related]
33. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
Nordin A; Wang W; Welén K; Damber JE
Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine differentiation in prostate cancer.
Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
[TBL] [Abstract][Full Text] [Related]
35. TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer.
Wen YC; Liu YN; Yeh HL; Chen WH; Jiang KC; Lin SR; Huang J; Hsiao M; Chen WY
Oncogenesis; 2021 Nov; 10(11):81. PubMed ID: 34799554
[TBL] [Abstract][Full Text] [Related]
36. Sympathetic signaling facilitates progression of neuroendocrine prostate cancer.
Dwivedi S; Bautista M; Shrestha S; Elhasasna H; Chaphekar T; Vizeacoumar FS; Krishnan A
Cell Death Discov; 2021 Nov; 7(1):364. PubMed ID: 34811362
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?
Grigore AD; Ben-Jacob E; Farach-Carson MC
Front Oncol; 2015; 5():37. PubMed ID: 25785244
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.
Li Y; Chen HQ; Chen MF; Liu HZ; Dai YQ; Lv H; Bing Zu X; Qi L
Life Sci; 2009 Jun; 84(25-26):882-7. PubMed ID: 19356736
[TBL] [Abstract][Full Text] [Related]
39. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
40. Studies of hormonal regulation, phenotype plasticity, bone metastasis, and experimental therapeutics in androgen-repressed human prostate cancer (ARCaP) model.
Lo UG; Chen YA; Khamis ZI; Kao WH; Hsieh JT; Sang QA
Am J Clin Exp Urol; 2021; 9(4):277-286. PubMed ID: 34541026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
